Galena halts clinical trial By: MarketMinute.com Stock News June 29, 2016 at 16:51 PM EDT Galena Biopharma Inc. (Nasdaq: GALE) will discontinue its Phase 3 PRESENT clinical trial due to futility. Shares of the biopharmaceutical plummeted $1.68 to close at $0.35.